Lys-MDA

  1. Home
  2. Wiki
Lys-MDA
Clinical data
Routes of
administration		Oral[1]
Drug classSerotonin–norepinephrine–dopamine releasing agent; Serotonin 5-HT2 receptor agonist; Entactogen; Empathogen; Serotonergic psychedelic; Hallucinogen; Stimulant
ATC code
  • None
Pharmacokinetic data
MetabolitesMDA[1]
Identifiers
  • (2S)-2,6-diamino-N-[1-(1,3-benzodioxol-5-yl)propan-2-yl]hexanamide
CAS Number
Chemical and physical data
FormulaC16H25N3O3
Molar mass307.394 g·mol−1
3D model (JSmol)
  • CC(Cc2ccc1OCOc1c2)NC(=O)C(N)CCCCN

Lys-MDA (Lysine-MDA, N-(L-lysinamidyl)-3,4-methylenedioxyamphetamine) is a substituted amphetamine derivative with empathogenic effects, which acts as a prodrug for MDA with a slower onset of effects and longer duration of action. Lys-MDA, along with the related derivative Lys-MDMA, are in early stage human clinical trials as potential treatments for treatment-resistant depression and post-traumatic stress disorder. New MDMA prodrugs are in the development phase at MiHKAL GmbH in Switzerland.[2][3][4][5] A phase 1 clinical trial comparing MDMA, MDA, Lys-MDMA, and Lys-MDA has been completed as of August 2024.[6] The trial results, which included pharmacodynamic and pharmacokinetic findings, was published in September 2025.[1]

See also

[edit]

References

[edit]
  1. ^ a b c Straumann I, Vizeli P, Avedisian I, Erne L, Noorshams D, Vukalovic I, Eckert A, Luethi D, Rudin D, Liechti ME (September 2025). "Acute effects of MDMA, MDA, lysine-MDMA, and lysine-MDA in a randomized, double-blind, placebo-controlled, crossover trial in healthy participants". Neuropsychopharmacology. doi:10.1038/s41386-025-02248-3. PMID 40999236.
  2. ^ Buntz B (21 September 2022). "MindMed announces Phase 1 study of MDMA-like substances". Drug Discovery and Development.
  3. ^ "MindMed Collaborators Dose First Patient in Phase 1 Investigator-Initiated Trial of MDMA-Like Substances". Biospace.com. 20 September 2022.
  4. ^ WO 2022/053696, Grill M, "Novel Safrylamine derivatives having prodrug properties.", published 17 March 2022, assigned to Compass Pathfinder Limited. 
  5. ^ WO 2023/283373, Clark S, Duncton MA, "Methylenedioxymethamphetamine and Related Psychedelics and Uses Thereof", published 12 January 2023, assigned to Terran Biosciences Inc. 
  6. ^ "ClinicalTrials.gov". ClinicalTrials.gov. 13 August 2024. Retrieved 13 November 2024.